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tivity of common cancer cell lines to PPARg agonists in a DOK1-depen-
dent manner. The potential for repurposing of PPARg agonists, an
established class of anti-diabetic medications, is one of the practical im-
plications of the results of the Burgermeister et al. paper. As for the clin-
ical relevance, the authors demonstrate that the loss of DOK1
expression portends worse survival in patients with colorectal cancer.DOK1In this issue, Burgermeister et al., present very interesting data on
the function of DOK1, an enigmatic multifunctional adaptor protein
(Friedrich et al., 2016). Previous studies nicely summarized by the au-
thors, have shown that DOK1 functions as a tumor suppressor by nega-
tively regulating signaling via its interaction with p120 RAS GTPase-
activating protein (GAP) to dampen MAPK signaling cascades down-
streamof receptor and non-receptor kinases in various cellular contexts
(Songyang et al., 2001; Shinohara et al., 2004; Zhao et al., 2006). Re-
markably, Dok-1 knockout studies demonstrated hematopoietic defects
(Yasuda et al., 2004) and development of sarcomas with the loss of
other DOKmembers (Mashima et al., 2010). The studies of DOK1 func-
tion were not only complicated by the presence of several protein iso-
forms encoded by the same DOK1, but also dynamic shifts of the
protein between the nucleus and the cytosol in resting and proliferating
cells, respectively. Regarding the docking of DOK1, the full-length p62
DOK1has anN-terminal plextrin homology (PH) domain formembrane
binding, and a phospho-tyrosine-binding (PTB) domain thought to be
involved in interactions with other protein partners. Unexpectedly,
the authors convincingly demonstrate that the C-terminal PTB domain
has yet another partner which directly regulates cell growth. And this
is when peroxisome proliferator-activated receptor gamma (PPARg)
enters the stage. Detailed experiments demonstrate not only them.2016.05.003.
. This is an open access article underphysical interactions between the two novel partners, but also a sensi-
Obviously, the devil is always in the detail. And those are multiple,
and generously supplied in the Supplement to the paper. Not only the
loss of DOK1, but also the expression of several isoforms with C- and
N-terminal truncations differs in between the analyzed cases. To make
matters even more complicated, patients' survival seemed to depend
on the DOK1 expression in the stroma suggesting a general role DOK1
in cell growth. Are these phenomena all mediated by PPARg? Or DOK1
continues to play many characters on the same stage shifting between
the cellular and tissue compartments and changing its size and docking
tools? The future will tell…References
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